// App-Quantinova.ai

2313 : Improved killing of tumor cells by a novel flexible antibody-based modular T cell retargeting system

Researchers

Presenter

  • Armin Ehninger

Principal Investigators

  • Marc Cartellieri

  • Anja Feldmann

  • Claudia Arndt

  • Stefanie Koristka

  • Simon Loff

  • Malte von Bonin

  • Gerhard Ehninger

  • Michael Bachmann

Medical Centers

  • GEMoaB GmbH, Dresden, Germany

  • Cellex Patient Treatment GmbH, Dresden, Germany

  • Institute of Radiopharmaceutical Cancer Research, HZDR Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany

  • Tumorimmunology, University Cancer Center (UCC), Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany

  • Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.

Locations

  • Germany

Companies

  • GEMoaB Monoclonals G

  • Cellex Patient Treat

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved